Cargando…

Author Correction: Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target

Detalles Bibliográficos
Autores principales:	Cook, Peter J., Thomas, Rozario, Kannan, Ram, de Leon, Esther Sanchez, Drilon, Alexander, Rosenblum, Marc K., Scaltriti, Maurizio, Benezra, Robert, Ventura, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857674/ https://www.ncbi.nlm.nih.gov/pubmed/29532792 http://dx.doi.org/10.1038/ncomms16187

Ejemplares similares

Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target
por: Cook, Peter J., et al.
Publicado: (2017)

Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
por: Alvarez-Breckenridge, Christopher, et al.
Publicado: (2017)

A canine BCAN microdeletion associated with episodic falling syndrome
por: Gill, Jennifer L., et al.
Publicado: (2012)

Molecular and clinicopathologic features of gliomas harboring NTRK fusions
por: Torre, Matthew, et al.
Publicado: (2020)

A Case of Infant-Type Hemispheric Glioma with NTRK1 Fusion
por: Garcia, Mekka R., et al.
Publicado: (2022)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

HGG-24. NTRK-rearranged infantile gliomas of suprasellar/ optic pathway origin
por: Lazow, Margot A, et al.
Publicado: (2022)

Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
por: König, David, et al.
Publicado: (2022)

Parallel Mapping and Simultaneous Sequencing Reveals Deletions in BCAN and FAM83H Associated with Discrete Inherited Disorders in a Domestic Dog Breed
por: Forman, Oliver P., et al.
Publicado: (2012)

Expression of the neurotrophic tyrosine kinase receptors, ntrk1 and ntrk2a, precedes expression of other ntrk genes in embryonic zebrafish
por: Hahn, Katie, et al.
Publicado: (2020)

Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
por: Rheinbay, Esther, et al.
Publicado: (2023)

Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas
por: Guerreiro Stucklin, Ana S., et al.
Publicado: (2019)

NTRK2 Fusion driven pediatric glioblastoma: Identification of oncogenic Drivers via integrative Genome and transcriptome profiling
por: Britton, Heidi M., et al.
Publicado: (2021)

Multi‐cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma
por: Yan, Junya, et al.
Publicado: (2023)

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
por: Somwar, Romel, et al.
Publicado: (2020)

BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior
por: Jones, Karra A., et al.
Publicado: (2019)

HGG-12. A CASE OF PEDIATRIC SPINAL HIGH-GRADE GLIOMA WITH NTRK1 GENE FUSION
por: Morisako, Tamaki, et al.
Publicado: (2020)

Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion
por: Keddy, Clare, et al.
Publicado: (2021)

HGG-37. A case ofETV6-NTRK3 fusion driven infantile hemispheric glioma (IHG) with acquired drug resistance against first- and second-generation NTRK-inhibitors
por: Ku, Dennis T L, et al.
Publicado: (2022)

Author Correction: Influence of environment on testing of hydraulic sealers
por: Benezra, Mira Kebudi, et al.
Publicado: (2018)

Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions
por: Brčić, Iva, et al.
Publicado: (2020)

Somatic evolutionary timings of driver mutations
por: Gomez, Karen, et al.
Publicado: (2018)

A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways
por: Pattwell, Siobhan S., et al.
Publicado: (2020)

NTRK1 Fusion in Glioblastoma Multiforme
por: Kim, Jinkuk, et al.
Publicado: (2014)

Identifying patients with NTRK fusion cancer
por: Solomon, J P, et al.
Publicado: (2019)

NTRK fusion in Japanese colorectal adenocarcinomas
por: Yamashiro, Yuya, et al.
Publicado: (2021)

NTRK insights: best practices for pathologists
por: Hechtman, Jaclyn F.
Publicado: (2021)

A review of NTRK fusions in cancer
por: Manea, Cristina Alexandra, et al.
Publicado: (2022)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
por: Farago, Anna F., et al.
Publicado: (2015)

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
por: Konicek, Bruce W., et al.
Publicado: (2018)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Author Correction: Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas
por: Kazarian, Eve, et al.
Publicado: (2021)

Germline and somatic drivers in inherited hematologic malignancies
por: Zoller, Julian, et al.
Publicado: (2023)

CHI3L1, NTRK2, 1p/19q and IDH Status Predicts Prognosis in Glioma
por: Deluche, Elise, et al.
Publicado: (2019)

DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer
por: Bashashati, Ali, et al.
Publicado: (2012)

Correction: NTRK1 Fusion in Glioblastoma Multiforme
Publicado: (2014)

NTRK fusions are extremely rare in bone tumours
por: Lam, Suk Wai, et al.
Publicado: (2021)

“SQiD, the Single Question in Delirium; can a single question help clinicians to detect delirium in hospitalised cancer patients?” running heading Single Question in Delirium” (Bcan-D-20-01665)
por: Sands, Megan B., et al.
Publicado: (2021)

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
por: Mayr, Lisa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kkqt1fvfgl9n2k3nijaqjlu39h